

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

FGF Receptor 1 (D8E4) XP Rabbit mAb

RRID:AB_11178519

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9740, RRID:AB_11178519

Antibody Information

URL: http://antibodyregistry.org/AB_11178519

Proper Citation: Cell Signaling Technology Cat# 9740, RRID:AB_11178519

Target Antigen: FGF Receptor 1 (D8E4) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_11178519, AB_11178808.

Antibody Name: FGF Receptor 1 (D8E4) XP Rabbit mAb

Description: This monoclonal targets FGF Receptor 1 (D8E4) XP Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_11178519

Vendor: Cell Signaling Technology

Catalog Number: 9740

Record Creation Time: 20250820T001005+0000

Record Last Update: 20250820T073312+0000

Ratings and Alerts

No rating or validation information has been found for FGF Receptor 1 (D8E4) XP Rabbit mAb.

No alerts have been found for FGF Receptor 1 (D8E4) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Juric D, et al. (2026) PI3K γ Inhibitor and Degradar Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 56.

Kostas M, et al. (2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. *Cell reports*, 45(6), 117504.

Yuan L, et al. (2025) STEAP3 promotes triple-negative breast cancer growth through the FGFR1-mediated activation of PI3K/AKT/mTOR signaling. *iScience*, 28(6), 112526.

Gu Y, et al. (2025) Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. *Angiogenesis*, 28(2), 13.

Madorsky Rowdo FP, et al. (2025) Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition. *Cancer research*, 85(3), 551.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8⁺T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Yeh CJ, et al. (2025) FGFR1 and FGFR4 are essential regulators of muscle stem cell quiescence. *Cell communication and signaling : CCS*, 23(1), 535.

Anastasaki C, et al. (2025) Aberrant coupling of glutamate and tyrosine kinase receptors enables neuronal control of brain-tumor growth. *Neuron*.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells. *Cell metabolism*, 36(3), 630.

Edman NI, et al. (2024) Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies. *Cell*, 187(14), 3726.

Choi YR, et al. (2023) Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. *British journal of cancer*.

Ma L, et al. (2023) Discovery of a Selective and Orally Bioavailable FGFR2 Degradar for Treating Gastric Cancer. *Journal of medicinal chemistry*, 66(11), 7438.

Vad-Nielsen J, et al. (2023) Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells. *Translational lung cancer research*, 12(1), 42.

Shin S, et al. (2023) mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching. *Cell reports*, 42(8), 112868.

Mitchell AV, et al. (2022) DDR2 coordinates EMT and metabolic reprogramming as a shared effector of FOXQ1 and SNAI1. *Cancer research communications*, 2(11), 1388.

Schaefer EJ, et al. (2022) BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. *Blood cancer discovery*, 3(2), 116.

Li H, et al. (2022) Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis. *Cell reports*, 41(12), 111834.